Evidence map›Paper›PMID 36685264›Full record

ArticleClinical and experimental hepatology2022

Diagnostic performance of

Hanan Nomeir, Heba Elsheredy, Azhar Nomeir, Neveen Rashad Mostafa, Shaymaa El-Hamshary

Open access · diamondAbstract read
In one paragraph

Article in Clinical and experimental hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 57% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Hanan NomeirAlexandria University, Egypt.
Heba ElsheredyAlexandria University, Egypt.
Azhar NomeirMedical Research Institute, Alexandria University, Egypt.
Neveen Rashad MostafaMedical Research Institute, Alexandria University, Egypt.
Shaymaa El-HamsharyDepartment of Biochemistry, Faculty of Science, Alexandria University, Egypt.
Alexandria University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aim of the study: This study aimed to evaluate the methylation status of two genes in the peripheral blood as possible non-invasive biomarkers for hepatocellular carcinoma (HCC) development in Egyptian patients with hepatitis C virus (HCV)-related liver cirrhosis, compare them with α-fetoprotein (AFP), and assess their relationship with the clinicopathological characteristics of the tumor. Material and methods: Thirty healthy volunteers, forty patients with HCC on top of HCV-associated liver cirrhosis, and forty patients with HCV-associated liver cirrhosis participated in this study. Using methylation-specific polymerase chain reaction (MSP), the methylation status of Results: The tumor group was significantly more methylated in both genes than the cirrhosis and the control groups. The Conclusions: Methylated

Indexed as

CDKN2ADNA methylationepigeneticsHCCRASSF1A

Identifiers

PMID36685264
PMCPMC9850312
OpenAlexW4296638987

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.